Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report sent to investors on Saturday. The firm issued a hold rating on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently issued reports on VNDA. Cantor Fitzgerald boosted their price target on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. HC Wainwright began coverage on Vanda Pharmaceuticals in a report on Thursday, October 31st. They set a “buy” rating and a $18.00 target price for the company.

Vanda Pharmaceuticals Stock Up 1.1 %

Shares of VNDA opened at $5.40 on Friday. Vanda Pharmaceuticals has a fifty-two week low of $3.32 and a fifty-two week high of $6.75. The company’s fifty day moving average is $4.79 and its two-hundred day moving average is $5.25. The firm has a market cap of $314.77 million, a PE ratio of -19.46 and a beta of 0.77.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its position in Vanda Pharmaceuticals by 70.1% during the 1st quarter. BNP Paribas Financial Markets now owns 101,363 shares of the biopharmaceutical company’s stock worth $417,000 after acquiring an additional 41,767 shares in the last quarter. Empowered Funds LLC boosted its stake in shares of Vanda Pharmaceuticals by 8.2% in the first quarter. Empowered Funds LLC now owns 201,283 shares of the biopharmaceutical company’s stock valued at $827,000 after purchasing an additional 15,215 shares during the period. Susquehanna Fundamental Investments LLC purchased a new position in shares of Vanda Pharmaceuticals in the first quarter valued at $1,158,000. Sei Investments Co. increased its stake in Vanda Pharmaceuticals by 39.6% during the 1st quarter. Sei Investments Co. now owns 518,851 shares of the biopharmaceutical company’s stock worth $2,132,000 after buying an additional 147,066 shares during the period. Finally, State Board of Administration of Florida Retirement System increased its stake in Vanda Pharmaceuticals by 142.4% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 56,002 shares of the biopharmaceutical company’s stock worth $230,000 after buying an additional 32,902 shares during the period. Hedge funds and other institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.